Dose-Proportionality and Food Effect Study of TNX-102 SL
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04164719
- Locations
- 🇨🇦
Canada, Quebec, Quebec City, Quebec, Canada
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT03841773
- Locations
- 🇺🇸
Ashild Peters, Dallas, Texas, United States
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Phase 3
Completed
- Conditions
- PTSD
- Interventions
- Drug: TNX-102 SL 5.6 mg
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT03508700
- Locations
- 🇺🇸
Little Rock, Little Rock, Arkansas, United States
🇺🇸Norwich, Norwich, Connecticut, United States
🇺🇸Tampa, Tampa, Florida, United States
Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03443960
- Locations
- 🇨🇦
Quebec City, Quebec City, Quebec, Canada
Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Drug: Treatment ADrug: Treatment B
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03168022
- Locations
- 🇨🇦
InVentiv Health Clinique Inc., Quebec, Canada
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT03110575
- Locations
- 🇺🇸
New York, New York, New York, United States
🇺🇸Orange, Orange, California, United States
🇺🇸Rogers, Rogers, Arkansas, United States
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT03062540
- Locations
- 🇺🇸
Chicago, Chicago, Illinois, United States
🇺🇸Lauderhill, Lauderhill, Florida, United States
🇺🇸Maitland, Maitland, Florida, United States
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
Phase 3
Terminated
- Conditions
- FibromyalgiaMuscular DiseasesNervous System DiseasesRheumatic DiseasesMyofascial Pain SyndromesNeuromuscular DiseasesMusculoskeletal Diseases
- Interventions
- Drug: TNX-102 SL Tablet, 2.8 mgDrug: Placebo SL Tablet
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02829814
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Phase 3
Completed
- Conditions
- Primary Fibromyalgia
- Interventions
- Drug: TNX-102 SL Tablet 2.8 mg
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT02589275
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Phase 3
Completed
- Conditions
- Myofascial Pain SyndromesFibromyalgiaMuscular DiseasesMusculoskeletal DiseasesNervous System DiseasesNeuromuscular DiseasesRheumatic Diseases
- Interventions
- Drug: TNX-102 SL Tablet, 2.8mgDrug: Placebo SL Tablet
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Tonix Pharmaceuticals, Inc.
- Target Recruit Count
- 519
- Registration Number
- NCT02436096
© Copyright 2025. All Rights Reserved by MedPath